Clinical Study Using Antiaging Glycopeptide (PKX-001) in Islet Transplantation

Trial Profile

Clinical Study Using Antiaging Glycopeptide (PKX-001) in Islet Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs PKX 001 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 09 Mar 2017 According to a Protokinetix media release, the fist patient has been treated in this trial.
    • 02 Mar 2017 Status changed to recruiting.
    • 17 Jan 2017 According to a ProtoKinetix media release, the Governors of the University of Alberta have submitted an investigational testing authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top